TL;DR
Turn quiet afternoons into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
Evidence connecting cholesterol-lowering drugs with Alzheimer’s remains mixed. A Danish observational study found lower dementia risk among people with Type 2 diabetes who started statins, while a Phase 3 trial subgroup showed that obicetrapib lowered the Alzheimer’s blood biomarker pTau-217 in ApoE4 carriers. Neither finding establishes that these drugs prevent or treat Alzheimer’s; a separate Phase 2b trial of obicetrapib is now testing biomarker effects in people without symptoms.
Cholesterol-lowering drugs have not been shown to prevent or treat Alzheimer’s, despite new findings that have renewed interest in the possibility. A Danish observational study linked statin use with lower dementia risk among people with Type 2 diabetes, and a Phase 3 trial subgroup found that obicetrapib lowered the blood biomarker pTau-217 in participants carrying the ApoE4 risk gene. Those results do not establish that either drug class changes cognitive decline or Alzheimer’s disease.
In a study published in Lancet Regional Health Europe, Shoaib Afzal, a physician and professor at Copenhagen University Hospital, analyzed health records for more than 130,000 people with Type 2 diabetes. People who began statins earlier had a 15% lower dementia risk over a decade, while those who started later had a 10% lower risk, according to the report. The study was observational, meaning it examined outcomes associated with treatment rather than randomly assigning participants to take statins or a placebo.
The newer drug finding concerns obicetrapib, a CETP inhibitor developed by NewAmsterdam Pharma. In a subgroup of 1,727 participants with heart disease or a genetic form of high cholesterol who carried ApoE4, the drug lowered blood levels of pTau-217, a biomarker used to help diagnose Alzheimer’s in people with cognitive impairment. The finding came from a Phase 3 trial, but the subgroup result was about a blood biomarker—not demonstrated improvement in memory, thinking, or disease progression.
NewAmsterdam has enrolled the first participant in a Phase 2b Alzheimer’s trial. The year-long study is intended to test whether obicetrapib can lower Alzheimer’s biomarkers in people who have disease hallmarks but no symptoms. The report does not provide a result from this trial.
Why the New Biomarker Finding Matters
The findings give researchers a reason to investigate whether some cholesterol-lowering treatments could affect processes linked to Alzheimer’s, but they do not support prescribing them for that purpose. A change in pTau-217 is not proof of a clinical benefit: it does not show that participants avoided dementia, retained cognitive abilities, or improved after treatment.
The distinction matters for patients and clinicians because statins are used to lower cardiovascular risk, and their role in Alzheimer’s remains unsettled. The Danish study raises a prevention question, while the obicetrapib result offers a separate biological signal to test. Neither answers whether treatment reduces Alzheimer’s risk or slows disease. Decisions about cholesterol medication should continue to be based on established medical indications, not an unproven Alzheimer’s benefit.
As an affiliate, we earn on qualifying purchases.
Why Statin Evidence Remains Mixed
Earlier randomized controlled trials of statins did not find that the drugs treated cognitive decline, according to the report. A more recent randomized trial in healthy adults over 70 also failed to find a dementia-prevention effect. Such trials are designed differently from observational research: random assignment helps reduce differences between people who take a medicine and those who do not.
Researchers have suggested that earlier trials may have been too short or begun too late to detect a prevention effect, but that possibility has not been established. Observational results also have a limitation: statin users may differ from nonusers in education, health care access, or other health behaviors. David Knopman, a Mayo Clinic neurologist, raised that concern in comments to Being Patient.
There is also a biological distinction between cholesterol in the blood and cholesterol metabolism in the brain. The report says blood cholesterol itself does not enter the brain, while abnormalities in cholesterol processing within the brain are being studied in relation to Alzheimer’s. Statins lower blood cholesterol but do not readily reach the brain, a reason some researchers doubt they directly alter brain cholesterol metabolism.
“I’m of the opinion that our traditional way of treating cholesterol with statins is probably not going to work.”
— Heather Ferris, University of Virginia clinical endocrinologist and scientist, speaking to Being Patient
blood biomarker testing kit for Alzheimer’s
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
What the Results Cannot Establish
The Danish study cannot show that statins caused the lower dementia risk, and the report does not establish that its findings apply to people without Type 2 diabetes. Differences between people who use statins and those who do not may help explain the association. The reported trial in healthy older adults also did not find a prevention effect.
For obicetrapib, the clinical meaning of the pTau-217 change is not yet known. The available account does not say whether the biomarker change corresponds to less Alzheimer’s pathology, preserved cognition, or a lower chance of developing symptoms. It also does not provide results from the ongoing Phase 2b study. More research is needed before the drug’s potential role in Alzheimer’s prevention or treatment can be judged.
As an affiliate, we earn on qualifying purchases.
The Obicetrapib Trial’s Next Test
The next reported milestone is the ongoing Phase 2b trial of obicetrapib, which will test biomarker changes after a year of treatment in people with Alzheimer’s hallmarks but no symptoms. The report does not give a timetable for results. Researchers would still need evidence connecting any biomarker change to meaningful cognitive or clinical outcomes before concluding that the drug prevents or treats Alzheimer’s.
For statins, the report says experts consider a long-term randomized prevention trial difficult to fund, in part because the drugs are off-patent. Until stronger evidence is available, the current findings are research signals—not a basis for changing cholesterol treatment to address Alzheimer’s.
As an affiliate, we earn on qualifying purchases.
Key Questions
Do statins prevent Alzheimer’s?
This has not been established. The Danish observational study found an association between statin use and lower dementia risk in people with Type 2 diabetes, but it cannot prove the drugs caused that difference. Randomized trials cited in the report did not show a dementia-prevention effect.
Does obicetrapib treat Alzheimer’s?
There is no evidence in the report that it treats Alzheimer’s. A subgroup analysis found lower blood pTau-217, but it did not show improved cognition or slower disease progression. A Phase 2b study is testing biomarker effects.
What is pTau-217?
pTau-217 is a blood biomarker used to help diagnose Alzheimer’s in people with cognitive impairment. A change in its blood level does not by itself establish a change in symptoms or disease progression.
Should I start or stop a cholesterol drug to prevent dementia?
The report does not support changing medication for Alzheimer’s prevention. Cholesterol medicines should be discussed with a qualified health professional in light of a person’s medical history and established cardiovascular indications.
Source: rss
Halloween Picks
halloween
As an affiliate, we earn on qualifying purchases.
